<DOC>
	<DOCNO>NCT00960661</DOCNO>
	<brief_summary>The study compare two combination therapy : 1 ) Combined Basal Insulin Glargine ( day ) , Exenatide ( twice day ) , Metformin Therapy ; 2 ) Combined Basal Insulin Glargine ( day ) , Bolus Insulin Lispro ( three time day ) , Metformin Therapy , subject Type 2 Diabetes Mellitus inadequate glycemic control .</brief_summary>
	<brief_title>A Trial Comparing Two Therapies : Basal Insulin/Glargine , Exenatide Metformin Therapy ( BET ) Basal Insulin/Glargine , Bolus Insulin Lispro Metformin Therapy ( BBT ) Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Have take basal insulin Glargine , dose ≥ 20 units/day , least 3 month prior study start . Have take basal insulin Glargine dose ≥ 20 units/day , combination 1 follow oral antidiabetic medication ( OAM ) regimens , least 3 month prior study start : Metformin immediaterelease metformin extendedrelease metformin alone maximum tolerated stable dose less 500 mg/day least 6 week prior study start ; Metformin immediaterelease metformin extendedrelease metformin maximum tolerate stable dose less 500 mg/day least 6 week prior study start sulfonylurea stable dose 6 week prior study start . Have HbA1C &gt; 7.0 % ≤ 10.0 % . Have body mass index ( BMI ) ≥ 25 ≤ 45 kg/m2 . Are currently take OAM describe allow concurrent use insulin per local product label . Have take 1 week within 1 month prior study start glucoselowering medication include either alone combination formulation , use drug weight loss ( example , prescription drug orlistat , sibutramine , phenylpropanolamine , rimonabant similar overthecounter medication ) . Have take insulin Glargine within 3 month prior study start 1 week . Are receive chronic ( lasting longer 2 week ) systemic glucocorticoid therapy ( exclude topical , intraocular , inhaled preparation ) within 4 week prior study start . Are currently enrol , discontinue within last 30 day , clinical trial involve offlabel use investigational drug device ( study drug/device use study ) , concurrently enrol type medical research judge scientifically medically compatible study . Have previously complete withdrawn study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>Byetta</keyword>
	<keyword>insulin lispro</keyword>
	<keyword>Humalog</keyword>
	<keyword>insulin glargine</keyword>
	<keyword>Lantus</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>